Trial Profile
A nationwide study assessing the time to cardioversion and risk of cardiovascular complications in patients treated with dabigatran or warfarin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Oct 2015
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin
- Indications Embolism
- Focus Adverse reactions; Therapeutic Use
- 21 Oct 2015 New trial record
- 02 Sep 2015 Results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology.